Quintiles has hired Brian Kelly as its new president of payer and provider solutions.
Kelly joins the firm from Aetna, where he was head of informatics.
The firm says his appointment is part of plans to grow its analytics offering in hospitals and health plans markets.
Of his new role he said: “Payers and providers are exerting greater influence within the biopharma industry. Quintiles’ customers recognise this shift and are eager to apply new methods to unlock the value of their drug therapies.”
Althea Technologies has named Rick Hancock its new CEO.
Formerly president for the firm, Hancock’s 30 year biotech career includes positions ar Eli Lilly, and Hybritech.
Also promoted is operations manager Chris Duffy – who now becomes senior VP of operations – as well as former compliance bod E.J. Brandreth, who is now senior VP of quality and regulatory.
Magda Marquet, co-Founder and co-Chairman of Althea Technologies said: "I am confident each executive will play a crucial role in leading Althea to continued future growth."
CRI Lifetree has appointed Ali Craig-Rodriguez as COO and Jose Marcos as East Coast director of clinical operations.
Craig-Rodriguez joins the firm from Comprehensive Clinical Development where she served as president. Marcos was previously VP of Phase I clinical operations, also for Comprehensive.
Jeff Kinell, CR’s CEO said:“As chief operating officer, Craig-Rodriguez will play a key role in strengthening our core areas of inpatient and outpatient psychiatry, and will lead the company's strategic growth plan in the areas of pain, human abuse liability, psychiatry, neurology and diabetes.”
“Marcos will support our leadership team in the day-to-day operations of our 60-bed facility in Marlton, New Jersey, and our new 24-bed specialty unit in West Philadelphia, Pennsylvania.”
John Cline has become VP of client services for Cenduit.
In his new role he will oversee project and account management.
Jogin Desai, Cenduit CEO, said: “Cline will be instrumental in taking Cenduit's customer service to the next level and contributing to the company's next phase of growth.”
Sigma-Aldrich has drafted in Michael Marberry as a director.
Currently president and CEO of engineered materials provider J.M. Huber Corporation, Marberry will help the firm in its latest expansion plans, including for biologics toxicology services.
Rakesh Sachdev, president and CEO of Sigma-Aldrich, said: "His broad background and international experience in leading a successful global company and in expanding into applied chemical and industrial markets will help Sigma-Aldrich in strategic efforts to enhance its leadership position in Life Science and High Technology."